ACE inhibitors and nephroprotection in chronic proteinuric nephropathies


Cite item

Full Text

Abstract

ACE inhibitors slow irreversible worsening of renal function in chronic kidney disease with proteinuria, that is due not only to their blood pressure lowering effect, but also to their ability to reduce proteinuria. The reference prove of ACE inhibitors nephroprotective action was shown in trials REIN and AASK, in which ramipril was used

References

  1. Remuzzi G., Bertani T. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 1998;339:1448-56.
  2. Wolf G. Angiotensin II: a pivotal factor in the progression of renal disease. Nephrol. Dial. Transplant. 1999;14(Suppl. 1):42-44.
  3. Dzau V.J., Berstein K., Celermajer K., et al. Pathophysiological and therapeutic importance of tissue ACE: a consensus report. Cardiovasc. Drugs Ther. 2002;16:149-60.
  4. Crowley S.D., Gurley S.B., Olivierio M.I., et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J. Clin. Invest. 2005;115:1092-99.
  5. Мухин Н.А., Козловская Л.В., Бобкова И.Н. Индуцируемые протеинурией механизмы ремоделирования тубуло-интерстиция и возможности нефропротекции при гломерулонефрите // Вестник РАМН. 2005. № 1. С. 3-8.
  6. Remuzzi G., Ruggenenti P., Perico N. Chronic renal disease: renoprotective benefits of renin-angiotensin system inhibition. Ann. Intern. Med. 2002;136:604-15.
  7. Тареева И.Е., Кутырина И.М., Николаев А.Ю. и др. Пути торможения развития хронической почечной недостаточности // Терапевтический архив. 2000. № 6. С. 9-14.
  8. Комитет экспертов Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). М., 2008.
  9. Chiurchiu C., Remuzzi G., Ruggenenti P. Angiotensin-converting enzyme inhibition and renal protection in non-diabetic patients: the data of meta-analyses. J. Am. Soc. Nephrol. 2005;16:S58-S63.
  10. Zucchelli P., Zuccala A., Borghi A., et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992;42:452-58.
  11. van Essen G.G., Apperloo A.J., Rensam P.L., et al. Are angiotensin converting enzyme inhibitors superior to beta-blockers in retarding progressive renal function decline? Kidney Int. 1997;63(Suppl.):58-62.
  12. Кутырина И.М., Тареева И.Е., Герасименко О.И. и др. Использование ингибиторов ангиотензинпревращающего фермента при хронических диффузных заболеваниях почек // Терапевтический архив. 1995. № 5. С. 20-24.
  13. Maschio G., Alberti D., Janin G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996;334(15):939-45.
  14. Locatelli F., Carbarns I.R., Maschio G., et al. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney Int. 1997;63(Suppl.):S63-S66.
  15. Pisoni R., Faraone R., Ruggenenti P., et al. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. J. Nephrol. 2002;15(4):428-30.
  16. Götz R., Drechsler U., Heidbreder E., et al. Effect of the angiotensin-converting enzyme inhibitor ramipril on proteinuria, blood pressure and kidney function in histologically confirmed glomerulonephritis with nephrotic syndrome. Z. Kardiol. 1988;77(Suppl. 3):65-68.
  17. Marre M., Hallab M., Billiard A., et al. Small doses of ramipril to reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes. J. Cardiovasc. Pharmacol. 1991;18(Suppl. 2):S165-S168.
  18. O'Brien R.C., Cooper M.E., Allen T.J., et al. Ramipril reduces albuminuria in diabetic rats fed a high protein diet. Clin. Exp. Pharmacol. Physiol. 1989;16(8):675-80.
  19. Thaiss F., Haas C., Helmchen U., et al. Angiotensin-converting enzyme inhibition in experimental in-situ immune complex glomerulonephritis: influence on renal function, proteinuria, and morphology. Nephrol. Dial. Transplant. 1996;11(1):40-46.
  20. Trevisan R., Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am. J. Hypertens. 1995;8(9):876-83.
  21. Stenvinkel P., Bolinder J., Alvestrand A. Short-term treatment with ramipril normalizes renal haemodynamics and the natriuretic response to a sodium load in type 1 diabetic patients with early nephropathy. Acta Diabetol. 1997;34(1):10-17.
  22. Fogari R., Zoppi A., Pasotti C., et al. Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function. J. Hum. Hypertens. 1995;9(2):131-35.
  23. Schnack C., Hoffmann W., Hopmeier P., et al. Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia. 1996;39(12):1611-16.
  24. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349(9069):1857-63.
  25. Ruggenenti P., Perna A., Gherardi G., et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet. 1998;352(9136):1252-56.
  26. Ruggenenti P., Perna A., Mosconi L., et al. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int. 1998;53(5):1209-16.
  27. Ruggenenti P., Perna A., Benini R., et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J. Am. Soc. Nephrol. 1999;10(5):997-1006.
  28. Ruggenenti P., Perna A., Gherardi G., et al. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am. J. Kidney Dis. 2000;35(6):1155-65.
  29. Ruggenenti P., Perna A., Remuzzi G. Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J. Am. Soc. Nephrol. 2001;12(12):2832-37.
  30. Ruggenenti P., Pagano E., Tammuzzo L., et al. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int. 2001;59(1):286-94.
  31. Ruggenenti P., Perna A., Zoccali C., et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen) J. Am. Soc. Nephrol. 2000;11(1):88-96.
  32. Ruggenenti P., Perna A., Loriga G., et al.; REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939-46.
  33. Ruggenenti P., Perna A., Benini R., et al. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J. Am. Soc. Nephrol. 1998;9(11):2096-101.
  34. Pedersen E.B., Bech J.N., Nielsen C.B., et al. A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over two years. Scand. J. Clin. Lab. Invest. 1997;57(8):673-81.
  35. Fogari R., Zoppi A., Corradi L., et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J. Hum. Hypertens. 1999;13(1):47-53.
  36. Herlitz H., Harris K., Risler T., et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol. Dial. Transplant. 2001;16(11):2158-65.
  37. Pisoni R., Ruggenenti P., Sangalli F., et al. Effect of high dose ramipril with or without indomethacin on glomerular selectivity. Kidney Int. 2002;62(3):1010-19.
  38. Russo L.M., Brammar G.C., Jerums G., et al. The effect of ramipril on albumin excretion in diabetes and hypertension: the role of increased lysosomal activity and decreased transforming growth factor-beta expression. J. Hypertens. 2003;21(2):419-28.
  39. Grandaliano G., Ranieri E., Monno R., et al. Ramipril inhibits in vitro human mesangial cell proliferation and platelet-derived growth factor expression. Exp. Nephrol. 1999;7(3):229-35.
  40. Sebekova K., Gazdíkova K., Syrova D., et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J. Hum. Hypertens. 2003;17(4):265-70.
  41. Agodoa L.Y., Appel L., Bakris G.L., et al.; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. J.A.M.A. 2001;285(21):2719-28.
  42. Contras G., Greene T., Agodoa L.Y., et al.; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Blood pressure control, drug therapy and kidney disease. Hypertension 2005;46:44-50.
  43. Wright J.T. Jr., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. J.A.M.A. 2002;288(19):2421-31.
  44. Lea J., Greene T., Hebert L., et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch. Intern. Med. 2005;165(8):947-53.
  45. Norris K., Bourgoigne J., Gassman J., et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am. J. Kidney Dis. 2006;48(5):739-51.
  46. Soergel M., Verho M., Wuhl E., et al. Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension. Pediatr. Nephrol. 2000;15(1-2):113-18.
  47. Wühl E., Mehls O., Schaefer F.; ESCAPE Trial Group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66(2):768-76.
  48. Seeman T., Dusek J., Vondrak K., et al. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases. Am. J. Hypertens. 2004;17(5 Pt .1):415-20.
  49. Knoll G.A., Cantarovitch M., Cole E., et al. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation-study design. Nephrol. Dial. Transplant. 2008;23(1):354-58.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies